TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00737711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: iv 0.6 micrograms/kg every 2 weeks
Study: NCT02407405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: orally 50 mg/dose, every 12 hours every day continuously (1 cycle = 28 days)
Study: NCT00615446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248; Gemcitabine
Description: Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
Study: NCT04899258

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femtosecond laser assisted LASIK
Description: Refractive surgery
Study: NCT01560637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UT-15C (treprostinil diolamine)
Description: UT-15C extended release oral tablet three times daily
Study: NCT00664313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg po daily for 112 doses (16 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given daily for 112 doses (16 weeks)
Study: NCT00790647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.0 mg/m2/dose D -6, D-3, D +1, D + 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 100 mg/m2/dose D -2, D -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: infusion of previously collected autologous stem cells
Study: NCT01824199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
Study: NCT00072293

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary lymph node dissection
Description: Axillary lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No axillary lymph node dissection
Description: Therapeutic conventional surgery
Study: NCT00006441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/Zidovudine
Description: 300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine/Zidovudine
Description: 300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir mesylate
Description: 1250 mg twice daily for 104 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelfinavir mesylate
Description: 1250 mg twice daily for 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 7.5 million units twice daily. Treatment will last until conclusion of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldesleukin
Description: 7.5 million units twice daily. Treatment will last until conclusion of study.
Study: NCT03506451

Intervention type: OTHER
Group type: OTHER
Intervention: Demographics questionnaires and the FACT HN questionnaire
Description: Patients will complete a baseline survey assessing socioeconomic household information, baseline symptoms, QOL, and financial toxicity, as well as attitudes toward cost conversations and educational handouts.
Study: NCT01166373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enrollment video
Description: Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SSLF
Description: sacrospinous ligament fixation to suspend the vaginal apex

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ULS
Description: uterosacral ligament suspension to suspend the vaginal apex

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMT
Description: perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: usual care both before and after prolapse surgery with respect to pelvic muscle training
Study: NCT02684812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Treatment until aneurysm treatment or maximum dosage of 4 gram
Study: NCT03464357

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: The BOLD (Blood-Oxygen-Level Dependent) signal obtained by fMRI reflects the rate of oxygenation of the blood in the brain. However, the hemodynamic response that corresponds to an inflow of oxygenated blood increases in regions that consume energy. Thus, it is possible, by the study of the BOLD signal, to know with a great precision the regions of the brain specially active during a given task.~The recorded signals reflect a neuronal activation. For each eye, recordings with and without flash visual stimulation are performed alternately.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: The BOLD (Blood-Oxygen-Level Dependent) signal obtained by fMRI reflects the rate of oxygenation of the blood in the brain. However, the hemodynamic response that corresponds to an inflow of oxygenated blood increases in regions that consume energy. Thus, it is possible, by the study of the BOLD signal, to know with a great precision the regions of the brain specially active during a given task.~The recorded signals reflect a neuronal activation. For each eye, recordings with and without flash visual stimulation are performed alternately.
Study: NCT02181023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide
Description: Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium Bromide
Description: Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium Bromide
Description: Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom
Study: NCT01728701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.
Study: NCT01713660

Intervention type: DEVICE
Group type: OTHER
Intervention: iFS Femtosecond Laser
Description: corneal incisions created by the femtosecond laser
Study: NCT01828671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Soy Flour Corn Tortilla
Description: Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a high amount of soy flour.
Study: NCT00509860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 16 mg/m2 by vein Daily Over 1 Hour x 5 Days
Study: NCT02156284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic behaviour by nurses
Description: Control group: patients without specific empathic behaviour~Intervention group: patients who received the empathic behaviour was performed by a trained nurse.
Study: NCT04053400

Intervention type: DRUG
Intervention: Ketamine
Study: NCT01728701

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (NS)
Description: Normal saline

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (NS)
Description: Normal saline
Study: NCT04171596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary care coordination
Description: A registered nurse currently employed at Duke Integrative Medicine, who is also trained as an integrative health coach, will serve in the PCC role. The intervention will flow as follows:~The PCC will call study participants every 2 months during the 6 months (more frequently as needed) for a semi-structured phone check-in, and will track the intervention through the REDCap database. The PCC will use guiding questions to frame the call, but will also:~Respond Ask follow-up questions Provide suggestions that are guided by the patient response and appropriateness to the individual situation and needs and scope of practice.~Prior to the call, the PCC will review the patient chart to see if any outstanding orders, medical visits due, and review the patient health goals (known as the pre-work).~The PCC will call the patient to provide intervention. If patient is not available, the PCC will leave a message, or contact via MyChart to see about scheduling a time to talk.
Study: NCT00890006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced imaging for radiotherapy planning and guidance
Description: Integration of MRI in the treatment planning process / Integration of daily cone-beam computed tomography (CBCT)
Study: NCT00664976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy
Description: Electroconvulsive therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.
Study: NCT06000514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sm29 Protein, Schistosoma Mansoni
Description: Sm29 cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentavalent antimony (Sbv)
Description: Placebo cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentavalent antimony (Sbv)
Description: Placebo cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
Study: NCT00512707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (open label)
Description: On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil citrate (open label)
Description: On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: Testosterone Gel 1%: Starting active dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: 3 tubes of placebo gel equivalent to the amount of the testosterone gel will be applied during the placebo-controlled testosterone gel intervention for 16 weeks..
Study: NCT01829334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART dental sealant
Description: ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin dental sealant
Description: Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium fluoride varnish
Description: Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver fluoride solution
Description: Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
Study: NCT03174236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.
Study: NCT04444778

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous positive airway pressure
Study: NCT03174236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzyl penicillin
Description: The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, however, the efficacy of this treatment has not been established in clinical trials.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension manufactured to match metronidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
Study: NCT03965910

Intervention type: OTHER
Group type: OTHER
Intervention: Demonstration the Importance of Early Rehabilitation in Stroke Patients Based on Diffusion Tensor Imaging Data
Description: Twenty-eight stroke patients aged 36-72 years admitted to the our Physical Medicine and Rehabilitation Outpatient Clinics were included in this prospective study. After the approval of the ethics committee, written informed consent was obtained from the patients after they were informed about the content and purpose of the study, the schedule of rehabilitation to be administered, and the features of cranial magnetic resonance imaging (MRI) to be performed. Patients with confirmed diagnosis of stroke by computed tomography and/or MRI techniques were randomized into two groups according to the onset of post-stroke rehabilitation. The patients were randomized according to the duration of their admission to our clinic for rehabilitation. Group 1 consisted of patients admitted to our clinic within 1-4 weeks after stroke; Group 2 consisted of patients admitted within 5-8 weeks after stroke.~Late initiation of rehabilitation in Group 2 patients is not a condition related to our clinic.

Intervention type: OTHER
Group type: OTHER
Intervention: Demonstration the Importance of Early Rehabilitation in Stroke Patients Based on Diffusion Tensor Imaging Data
Description: Twenty-eight stroke patients aged 36-72 years admitted to the our Physical Medicine and Rehabilitation Outpatient Clinics were included in this prospective study. After the approval of the ethics committee, written informed consent was obtained from the patients after they were informed about the content and purpose of the study, the schedule of rehabilitation to be administered, and the features of cranial magnetic resonance imaging (MRI) to be performed. Patients with confirmed diagnosis of stroke by computed tomography and/or MRI techniques were randomized into two groups according to the onset of post-stroke rehabilitation. The patients were randomized according to the duration of their admission to our clinic for rehabilitation. Group 1 consisted of patients admitted to our clinic within 1-4 weeks after stroke; Group 2 consisted of patients admitted within 5-8 weeks after stroke.~Late initiation of rehabilitation in Group 2 patients is not a condition related to our clinic.
Study: NCT00680667

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coriolus versicolor extract
Description: Trametes versicolor (Tv) capsules at the assigned dose level (3 grams/day up to 24 grams/day) twice a day every day and continuing for weeks.
Study: NCT04271605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and exercise suggestion
Description: diet and exercise suggestion according to blood biochemistry data and bone mineral density
Study: NCT02642289

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Description: Probiotic 5000, a commercial probiotic product provided by the company Complementos Fitonutricionales, S.L.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Rhamnosus GG ®
Description: Ergyphilus confort, a commercial probiotic product provided by the nutritional supplements lab Laboratorios Nutergia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Innocuous substance
Study: NCT02387853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100
Study: NCT04648956

Intervention type: OTHER
Intervention: Standard treatment
Description: Participants shall fill the ICOAP-Ar questionnaire three times within one month in addition to other questionnaires including the KOOS/HOOS, and the Global Rating of Change Scale (GRoC). The first two times will be within a time frame of 48-72 hours. The third time will be after one month.
Study: NCT02309879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine infusion
Description: Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine infusion
Description: Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
Study: NCT03979014

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasill 9™ vaccine
Description: 3 doses of Gardasill 9™ vaccine 0.5 ml administered 3 times at 0, 2 and 6 month
Study: NCT04664972

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel +doxorubicin+ cyclophosphamide
Description: The control group was treated with TAC (docetaxel 75 mg / m2 + adriamycin 50 mg / m2 + cyclophosphamide 500 mg / m2) for 6 cycles, 21 days was a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel +Cisplatin
Description: The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
Study: NCT01719874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCN-032

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Study: NCT04415307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture over acupoints.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Far-Infrared heat-patch attachment
Description: Far-Infrared heat-patch attachment over acupoints.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and Fir-Infrared heat-patch attachment
Description: Acupuncture and Far-Infrared heat-patch attachment over acupoints.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Far-Infrared heat-patch attachment over acupoints without electric current passing.
Description: Far-Infrared heat-patch attachment over acupoints without electric current passing.
Study: NCT02590094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab or intravitreal ziv-aflibercept
Description: Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab or intravitreal ziv-aflibercept
Description: Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab or intravitreal ziv-aflibercept
Description: Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab or intravitreal ziv-aflibercept
Description: Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab or intravitreal ziv-aflibercept
Description: Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.